ClinicalTrials.gg
RecruitingNCT05523817Updated Oct 9, 2026

Targeting Specific Brain Networks to Treat Specific Symptoms in Depression

An interventional study of Intermittent Theta Burst Stimulation (iTBS) in Major Depressive Disorder, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Oct 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Depressive Disorder, Major by Massachusetts General Hospital — 9 open to participants now, 12 under way, none of them phase 3. Depressive Disorder, Major · Massachusetts General Hospital.

Planned enrollment
23rd of 77
80 · median 40
Started
2024
with 1 other
No phase
41 of 88
4 open now
Primary completion
2028-05
later than 9 of 11 live
Registered
80th of 88
by date

Among the 88 studies in Depressive Disorder, Major by Massachusetts General Hospital, this one is the 23rd largest by planned enrollment of the 77 interventional ones that give a count, is one of 2 that started in 2024, is one of 41 with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 80th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

9 of the 88 studies in Depressive Disorder, Major by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Depressive Disorder, Major by Massachusetts General Hospital, or all of them as a file.
02

Study summary

Repetitive transcranial magnetic stimulation (rTMS) is a way of non-invasively stimulating specific brain networks and is an established treatment for Major Depressive Disorder (MDD). This proposal will reveal network mechanisms of the therapeutic effects of rTMS by investigating how stimulating each network specifically changes network connectivity and behavior. This will be done in a highly individualized manner in depressed and healthy patients, leading to more effective and more individualized treatments for depression.

Read the detailed description

Network models are increasingly invoked to characterize the neurobiological underpinnings of mental illnesses. Dysfunction within specific circuits promotes the formation of specific symptoms. This suggests an opportunity to treat specific symptoms by modulating specific circuits. Repetitive transcranial magnetic stimulation (rTMS) is capable of circuit-specific neuromodulation. It is also an established treatment for Major Depressive Disorder (MDD). Clinical experience suggests that rTMS treats different symptom constructs by stimulating different circuits. However, there remains a critical lack of mechanistic evidence to support putative network mechanisms of rTMS, limiting its ability to treat patients with more personalized and optimized approaches. This mechanistic proposal will first use resting-state functional connectivity (FC) MRI and customized analytic pipelines to characterize functional network topography in healthy and depressed individuals at high resolution.This data will be used to derive rTMS targets functionally situated in discrete prefrontal networks (e.g., control, default, salience, limbic/reward). Next, patients will take part in a within-subject design in which they undergo rTMS to each target on separate days. Each target will be stimulated four times on a given day, and after each stimulation changes will be measured with: (1) REST-BOLD MRI (to assess FC changes), (2) TASK-BOLD MRI (to assess changes in BOLD activation on paradigms validated to test RDoC constructs), (3) state-based questionnaires or (4) neuropsychological tests. This work will facilitate individualized neuromodulation approaches based on network topography. This will pollinate large-scale clinical trials assessing the effects of differential circuit modulation. It will also illuminate circuit-construct relationships across neuropsychiatric disorders.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years of age
  • Capacity to provide form to participate in the study

Inclusion Criteria for participants with Major Depressive Disorder (MDD):

  • 18-65 years of age
  • Capacity to provide informed consent form to participate in the study
  • Currently in a major depressive episode. Comorbid anxiety disorders and personality disorders will be allowed provided that MDD is the primary diagnosis.

Exclusion criteria

Exclusion Criteria for all participants:

  • Meeting criteria, in the past or currently, for bipolar affective disorder, hypomania or mania.
  • Meeting criteria, in the past or currently, for a primary psychotic disorder (e.g., schizophrenia).
  • Neurological conditions with known structural brain lesions, e.g., intracranial masses, multiple sclerosis.
  • Any personal history of seizures or a family history of epilepsy in a first-degree relative.
  • Metal in the body that is ferromagnetic or metallic injury to the eyes.
  • Implanted pacemakers, medication pumps, vagal stimulators, deep brain stimulators, or ventriculoperitoneal shunts, etc.
  • Substance abuse or dependence that is current and active within the last six months, as indicated by self-report (e.g., heroin, cocaine, methamphetamines).
  • Inability to meet the safety criteria for MRI scanning for any other reason.
  • Severe or unstable medical illness.
  • Currently pregnant, as assessed with urine pregnancy test in women of childbearing age.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    DLPFC Salience network target

    iTBS delivered four times daily to an individually defined salience network representation in left dorsolateral prefrontal cortex (DLPFC).

    Device: Intermittent Theta Burst Stimulation (iTBS)

  • Experimental
    DLPFC Control network target

    iTBS delivered four times daily to an individually defined control network representation in left dorsolateral prefrontal cortex (DLPFC).

    Device: Intermittent Theta Burst Stimulation (iTBS)

  • Experimental
    DLPFC Default network A target

    iTBS delivered four times daily to an individually defined default network A representation in left dorsolateral prefrontal cortex (DLPFC).

    Device: Intermittent Theta Burst Stimulation (iTBS)

  • Experimental
    dmPFC Default network B target

    iTBS delivered four times daily to an individually defined default network B representation in left dorsomedial prefrontal cortex (DMPFC).

    Device: Intermittent Theta Burst Stimulation (iTBS)

  • Experimental
    vmPFC limbic-reward network target

    iTBS delivered four times daily to an individually defined reward network representation in left ventromedial prefrontal cortex (vMPFC).

    Device: Intermittent Theta Burst Stimulation (iTBS)

  • Sham comparator
    SHAM stimulation

    SHAM iTBS delivered four times daily to an individually defined SHAM region in left dorsolateral prefrontal cortex (DLPFC).

    Device: Intermittent Theta Burst Stimulation (iTBS)

Interventions

  • DeviceIntermittent Theta Burst Stimulation (iTBS)

    iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.

    Also known as: Repetitive Transcranial Magnetic Stimulation

06

What researchers measure

Primary outcomes

  1. Resting-state functional connectivity (FC)

    Changes in connectivity within and between brain networks

    Time frame: 1 hour

  2. Blood oxygenation level dependent (BOLD) activation

    Changes in activation resulting from performing a specific functional MRI (fMRI) task

    Time frame: 1 hour

  3. Applied Cognition-General Concerns scale

    Subjects rate how statements about cognition and attention apply to them, e.g., "Thinking is foggy." Score range is 8-40, with higher scores indicating lesser cognitive concerns.

    Time frame: 10 minutes

  4. Profile of Mood States Tension subscale

    Subjects are asked to rate how much certain adjectives about their mood apply to them at that moment, e.g., "tense", "nervous", "shaky." Score range: 0-28, higher scores indicating more tension.

    Time frame: 5 minutes

  5. Profile of Mood States Vigor subscale

    Subjects rate how much mood adjectives apply to them at that moment, e.g., "full of pep," "energetic," "vigorous." Score range 0-28, higher scores indicating more vigor.

    Time frame: 5 minutes

  6. Profile of Mood States Dejection subscale

    Subjects rate how much mood adjectives apply to them at that moment, e.g., "unworthy." Score range 0-28, higher scores indicating higher dejection.

    Time frame: 5 minutes

  7. State Shame and Guilt Scale

    Subjects rate how much certain statements apply to them, e.g., "I feel regret." Score range is 10-50, higher scores indicate more shame/guilt.

    Time frame: 5-10 minutes

  8. Fawcett-Clark Pleasure Capacity Scale

    Subjects anticipate how much they would enjoy a certain scenario, e.g., "you sit watching a beautiful sunset in an isolated part of the world." Score range is 36 to 180, higher scores indicate higher pleasure capacity.

    Time frame: 5-10 minutes

  9. Digit-Span Test

    Subjects repeat number lists in forward or reverse order (maximum score is 8 forwards and 8 backwards, higher scores indicate better performance).

    Time frame: 5 minutes

  10. Tower of London Task

    Subjects plan a series of moves to match a start set to a goal set.

    Time frame: 5-10 minutes

  11. Delayed Match to Sample Task

    Subjects match patterns to a recently viewed sample pattern. Score ranges from 0-30, with higher scores indicating better performance.

    Time frame: 5 minutes

  12. The Simon Test

    Subjects press different buttons based on incongruent spatial and/or color cues. Scores range from 0-30, with higher scores indicating better performance.

    Time frame: 5 minutes

  13. Face-name Associative Paradigm

    Subjects must remember names paired with certain faces (DN-A). Scores range from 0-32, with higher scores indicating better performance.

    Time frame: 30 minutes

  14. Reading the Mind Through the Eyes Test

    Subjects judge another person's mental state by looking at pictures of only their eyes. Score ranges from 0-41, higher scores indicate better performance.

    Time frame: 10 minutes

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Eldaief MC, Halko MA, Buckner RL, Pascual-Leone A. Transcranial magnetic stimulation modulates the brain's intrinsic activity in a frequency-dependent manner. Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21229-34. doi: 10.1073/pnas.1113103109. Epub 2011 Dec 12. PubMed 22160708 ↗
  • Fox MD, Halko MA, Eldaief MC, Pascual-Leone A. Measuring and manipulating brain connectivity with resting state functional connectivity magnetic resonance imaging (fcMRI) and transcranial magnetic stimulation (TMS). Neuroimage. 2012 Oct 1;62(4):2232-43. doi: 10.1016/j.neuroimage.2012.03.035. Epub 2012 Mar 19. PubMed 22465297 ↗

Individual participant data

Plan to share: No — This project will adhere to the NIH Grant Policy on Sharing of Unique Research Resources including the Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources. The results of this research will be made available via publication in scientific journals and through scientific meetings where our findings are reported. Publication of data shall occur during the project, if appropriate, or at the end of the project, consistent with normal scientific practices. All publications will be made publicly available consistent with NIH policies. Such research data will be redacted to prevent the disclosure of personal identifiers.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for May 2028, 50 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 50 months is above that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Dec 2027 → May 2028 and completion Dec 2028 → May 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2022
First posted
Aug 31, 2022
StartActual
Mar 12, 2024
Primary completionEst.
May 31, 2028was Dec 2027
CompletionEst.
May 31, 2029was Dec 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2027→May 31, 2028
Oct 9, 2026
Study completion
Dec 31, 2028→May 31, 2029
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Dec 31, 2027→May 31, 2028
    Study completion Dec 31, 2028→May 31, 2029
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05523817
Responsible party
Mark C. Eldaief, MD (Assistant Professor of Neurology, Massachusetts General Hospital) — Principal investigator
First posted
Aug 31, 2022
Start date
Mar 12, 2024
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Oct 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion